Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS

(NOVN)
  Report  
Delayed Quote. Delayed Swiss Exchange - 09/13 11:31:24 am
86.66 CHF   -1.52%
09/14NOVARTIS : Trial and Error -2-
DJ
09/14NOVARTIS : Trial and Error
DJ
09/14NOVARTIS : The Startup That Manipulated Data to Get a -2-
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Novartis : UK Health Watchdog Recommends Novartis Gene Therapy for Sight Disorder

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/04/2019 | 01:15am EDT

By Carlo Martuscelli

A U.K. regulator said Wednesday that it is recommending that the National Health Service in England provides Luxturna, a gene therapy for an inherited eye disease developed by Switzerland's Novartis AG (NOVN.EB).

In its decision, the National Institute for Health and Care Excellence noted that it was able to negotiate down the therapy from its list price of 613,410 pounds ($742,084) per patient. It didn't disclose the final price it reached with Novartis.

"The company's willingness to work with us early and constructively has allowed us to publish this guidance on a much faster timeline than normal which is good news for patients," said Meindert Boysen, director of NICE's Centre for Health Technology Evaluation.

The recommendation is for people with vision loss caused by inherited retinal dystrophy from a mutation in the RPE65 gene. The disease involves progressive loss of vision until near-total blindness.

Luxturna is a one-time treatment that is intended to provide patients with a working copy of the faulty gene. According to Novartis, it is able to restore vision in people with the retinal disease.

The Swiss pharmaceutical company estimates that some 86 patients are eligible for treatment in England. NICE said that the recommendation is currently at the draft stage. Barring appeals, it expects to publish its final guidance next month.

Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS
09/14NOVARTIS : Trial and Error -2-
DJ
09/14NOVARTIS : Trial and Error
DJ
09/14NOVARTIS : The Startup That Manipulated Data to Get a -2-
DJ
09/14NOVARTIS : The Startup That Manipulated Data to Get a Miracle Drug to Market
DJ
09/13NOVARTIS : New Novartis data show Mayzent can help preserve mobility for longer ..
AQ
09/13NOVARTIS : New Novartis data show that neuronal and glial filaments, biomarkers ..
PU
09/12NOVARTIS : New Novartis data show Mayzent® can help preserve mobility for longer..
PU
09/11Swiss Biotech Anokion Raises $40 Million in Series B Round
DJ
09/10NOVARTIS : NATIONALLY RANKED ROSEN LAW FIRM Continues To Investigate Securities ..
BU
09/10NOVARTIS : data confirm long-term efficacy and safety of Aimovig for majority of..
AQ
More news
Financials (USD)
Sales 2019 46 926 M
EBIT 2019 13 830 M
Net income 2019 10 117 M
Debt 2019 17 463 M
Yield 2019 3,39%
P/E ratio 2019 18,9x
P/E ratio 2020 20,6x
EV / Sales2019 4,64x
EV / Sales2020 4,28x
Capitalization 200 B
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 94,54  $
Last Close Price 87,47  $
Spread / Highest target 22,9%
Spread / Average Target 8,08%
Spread / Lowest Target -6,80%
EPS Revisions
Managers
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Srikant T. Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS18.45%200 777
JOHNSON & JOHNSON1.07%345 150
ROCHE HOLDING LTD.10.52%236 116
MERCK AND COMPANY8.11%211 513
PFIZER-15.44%204 151
NOVO NORDISK AS14.89%118 168